CosmoPHOS-nano is a multidisciplinary translational and
business-oriented project aiming to develop and evaluate in both nonclinical and
clinical applications a novel theranostic (diagnostic & therapeutic)
nanotechnology-enabled portable combination system which will enable:

The CosmoPHOS System is anticipated to reduce
the number of deaths and morbidity caused by CAD by up to 40%, which we forecast to result in
a significant decrease in European and global healthcare costs caused
by CAD, increase the income of the European healthcare industry
from the CAD market, which is the global largest, and alleviate the European
and Global Society.

The CosmoPHOS-nano Project is the world's largest R&D Project of Nanomedicine in
Cardiology, consisting of 19 world-class Participants including 13 Universities
and Research Foundations and 6 Companies. These academic and industrial partners
have spent more than nine years successfully collaborating, and the CosmoPHOS-nano
project marks a significant milestone in the Consortium's ongoing efforts to combat
the devastating effect of CAD on European and global societies.

The CosmoPHOS-nano project has been partially funded by the European Union Seventh Framework Programme (FP7)